News >

BRAF/MEK Combo New Standard for BRAF-Mutant NSCLC

Silas Inman @silasinman
Published: Tuesday, Aug 01, 2017

David R. Gandara, MD

David R. Gandara, MD
Targeted therapies are beginning to carve out a growing number of indications in non–small cell lung cancer (NSCLC), emphasizing the importance of precision medicine. The BRAF V600E mutations, which is present in 1% to 2% of NSCLC, was recently added to the list of potential targets, with an FDA approval for the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in June 2017.

gene mutations. As precision medicine continues to expand in NSCLC, NGS will continue to play an important role, although reimbursement for these tests remains a challenge, Gandara concluded.
Planchard D, Besse B, Kim TM, et al. Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. J Clin Oncol. 2017;35 (suppl; abstr 9075).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication